These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 35339046)

  • 1. Prevalence, severity, outcomes, and risk factors of COVID-19 in multiple sclerosis: An observational study in the Middle East.
    Alroughani R; Inshasi J; Al-Hashel J; Alkhaboury J; Alsalti A; Al Suwaidi R; Hassino LH; Farouk Ahmed S
    J Clin Neurosci; 2022 May; 99():311-316. PubMed ID: 35339046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Characteristics and Outcomes in Patients With Coronavirus Disease 2019 and Multiple Sclerosis.
    Louapre C; Collongues N; Stankoff B; Giannesini C; Papeix C; Bensa C; Deschamps R; Créange A; Wahab A; Pelletier J; Heinzlef O; Labauge P; Guilloton L; Ahle G; Goudot M; Bigaut K; Laplaud DA; Vukusic S; Lubetzki C; De Sèze J; ; Derouiche F; Tourbah A; Mathey G; Théaudin M; Sellal F; Dugay MH; Zéphir H; Vermersch P; Durand-Dubief F; Françoise R; Androdias-Condemine G; Pique J; Codjia P; Tilikete C; Marcaud V; Lebrun-Frenay C; Cohen M; Ungureanu A; Maillart E; Beigneux Y; Roux T; Corvol JC; Bordet A; Mathieu Y; Le Breton F; Boulos DD; Gout O; Guéguen A; Moulignier A; Boudot M; Chardain A; Coulette S; Manchon E; Ayache SS; Moreau T; Garcia PY; Kumaran D; Castelnovo G; Thouvenot E; Taithe F; Poupart J; Kwiatkowski A; Defer G; Derache N; Branger P; Biotti D; Ciron J; Clerc C; Vaillant M; Magy L; Montcuquet A; Kerschen P; Coustans M; Guennoc AM; Brochet B; Ouallet JC; Ruet A; Dulau C; Wiertlewski S; Berger E; Buch D; Bourre B; Pallix-Guiot M; Maurousset A; Audoin B; Rico A; Maarouf A; Edan G; Papassin J; Videt D
    JAMA Neurol; 2020 Sep; 77(9):1079-1088. PubMed ID: 32589189
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disease-modifying therapies, outcomes, risk factors and severity of COVID-19 in multiple sclerosis: A MENACTRIMS registry based study.
    Zeineddine M; Al-Hajje A; Salameh P; Massouh J; Saab G; Al-Roughani R; Ahmed SF; Al-Mahdawi A; Shalaby N; Inshasi J; Sahraian MA; Gouider R; Mrabet S; Al-Khabouri J; Shayganneja V; Chentouf A; Boumediene F; Yamout B
    Mult Scler Relat Disord; 2024 Oct; 90():105790. PubMed ID: 39121598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of Getting COVID-19 in People With Multiple Sclerosis: A Case-Control Study.
    Iaffaldano P; Lucisano G; Manni A; Paolicelli D; Patti F; Capobianco M; Brescia Morra V; Sola P; Pesci I; Lus G; De Luca G; Lugaresi A; Cavalla P; Montepietra S; Maniscalco GT; Granella F; Ragonese P; Vianello M; Brambilla L; Totaro R; Toscano S; Malucchi S; Petracca M; Moiola L; Ferraro D; Lepore V; Mosconi P; Ponzio M; Tedeschi G; Comi G; Battaglia MA; Filippi M; Amato MP; Trojano M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Mar; 9(2):. PubMed ID: 35046084
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COVID-19 in multiple sclerosis patients and risk factors for severe infection.
    Chaudhry F; Bulka H; Rathnam AS; Said OM; Lin J; Lorigan H; Bernitsas E; Rube J; Korzeniewski SJ; Memon AB; Levy PD; Schultz L; Javed A; Lisak R; Cerghet M
    J Neurol Sci; 2020 Nov; 418():117147. PubMed ID: 32980780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations of Disease-Modifying Therapies With COVID-19 Severity in Multiple Sclerosis.
    Simpson-Yap S; De Brouwer E; Kalincik T; Rijke N; Hillert JA; Walton C; Edan G; Moreau Y; Spelman T; Geys L; Parciak T; Gautrais C; Lazovski N; Pirmani A; Ardeshirdavanai A; Forsberg L; Glaser A; McBurney R; Schmidt H; Bergmann AB; Braune S; Stahmann A; Middleton R; Salter A; Fox RJ; van der Walt A; Butzkueven H; Alroughani R; Ozakbas S; Rojas JI; van der Mei I; Nag N; Ivanov R; Sciascia do Olival G; Dias AE; Magyari M; Brum D; Mendes MF; Alonso RN; Nicholas RS; Bauer J; Chertcoff AS; Zabalza A; Arrambide G; Fidao A; Comi G; Peeters L
    Neurology; 2021 Nov; 97(19):e1870-e1885. PubMed ID: 34610987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
    Sormani MP; De Rossi N; Schiavetti I; Carmisciano L; Cordioli C; Moiola L; Radaelli M; Immovilli P; Capobianco M; Trojano M; Zaratin P; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Ann Neurol; 2021 Apr; 89(4):780-789. PubMed ID: 33480077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multiple sclerosis, neuromyelitis optica spectrum disorder and COVID-19: A pandemic year in Czechia.
    Stastna D; Menkyova I; Drahota J; Mazouchova A; Adamkova J; Ampapa R; Grunermelova M; Peterka M; Recmanova E; Rockova P; Rous M; Stetkarova I; Valis M; Vachova M; Woznicova I; Horakova D
    Mult Scler Relat Disord; 2021 Sep; 54():103104. PubMed ID: 34216998
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Depression, anxiety, and fear of COVID-19 in patients with multiple sclerosis in pandemic era: a cross-sectional study.
    Alirezaei M; Eskandarieh S; Sahraian MA; Naser Moghadasi A
    Neurol Sci; 2022 Jan; 43(1):59-66. PubMed ID: 34554334
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A; Cárdenas-Robledo S; Tagliani P; Arrambide G; Otero-Romero S; Carbonell-Mirabent P; Rodriguez-Barranco M; Rodríguez-Acevedo B; Restrepo Vera JL; Resina-Salles M; Midaglia L; Vidal-Jordana A; Río J; Galan I; Castillo J; Cobo-Calvo Á; Comabella M; Nos C; Sastre-Garriga J; Tintore M; Montalban X
    Eur J Neurol; 2021 Oct; 28(10):3384-3395. PubMed ID: 33340215
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The outcome of a national MS-Covid-19 study: What the Turkish MS cohort reveals?
    Sen S; Karabudak R; Schiavetti I; Demir S; Ozakbas S; Tutuncu M; Petek Balci B; Turan OF; Uzunkopru C; Koseoglu M; Yetkin MF; Gunduz T; Gumus H; Kale Icen N; Carmisciano L; Terzi M; Acar P; Gungor Dogan I; Baba C; Tuncer A; Uygunoglu U; Sormani MP; Efendi H; Siva A;
    Mult Scler Relat Disord; 2021 Jul; 52():102968. PubMed ID: 33940495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Outcome of COVID-19 in Pediatric-Onset Multiple Sclerosis Patients.
    Oncel I; Alici N; Solmaz I; Oge DD; Ozsurekci Y; Anlar B
    Pediatr Neurol; 2022 Sep; 134():7-10. PubMed ID: 35772229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical course and outcome of SARS-CoV-2 infection in multiple sclerosis patients treated with disease-modifying therapies - the Polish experience.
    Czarnowska A; Brola W; Zajkowska O; Rusek S; Adamczyk-Sowa M; Kubicka-Bączyk K; Kalinowska-Łyszczarz A; Kania K; Słowik A; Wnuk M; Marona M; Podlecka-Piętowska A; Nojszewska M; Zakrzewska-Pniewska B; Jasińska E; Gołuch K; Lech B; Noga M; Perenc A; Popiel M; Lasek-Bal A; Puz P; Maciejowska K; Kucharska-Lipowska M; Lipowski M; Kapica-Topczewska K; Chorąży M; Tarasiuk J; Kochanowicz J; Kulikowska J; Wawrzyniak S; Niezgodzińska-Maciejek A; Pokryszko-Dragan A; Gruszka E; Budrewicz S; Białek M; Kurkowska-Jastrzębska I; Kurowska K; Stępień A; Włodek A; Ptasznik V; Pawełczyk M; Sobolewski P; Lejmel H; Strzalińska K; Maciejowski M; Tutaj A; Zwiernik J; Litwin A; Lewańczyk B; Paprocka I; Zwiernik B; Pawlos A; Borysowicz A; Narożnik A; Michałowska A; Nosek K; Fudala M; Milewska-Jędrzejczak M; Kułakowska A; Bartosik-Psujek H
    Neurol Neurochir Pol; 2021; 55(2):212-222. PubMed ID: 33856686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidence and Impact of COVID-19 in MS: A Survey From a Barcelona MS Unit.
    Sepúlveda M; Llufriu S; Martínez-Hernández E; Català M; Artola M; Hernando A; Montejo C; Pulido-Valdeolivas I; Martínez-Heras E; Guasp M; Solana E; Llansó L; Escudero D; Aldea M; Prats C; Graus F; Blanco Y; Saiz A
    Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33504634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical characteristics and outcomes of multiple sclerosis patients with COVID-19 in Toronto, Canada.
    Solomon JM; Jones A; Hohol M; Krysko KM; Muccilli A; Roll A; Rotstein D; Schneider R; Selchen D; Vosoughi R; Baral SD; Oh J
    Mult Scler Relat Disord; 2022 Feb; 58():103509. PubMed ID: 35030366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19 Severity in Multiple Sclerosis: Putting Data Into Context.
    Sormani MP; Schiavetti I; Carmisciano L; Cordioli C; Filippi M; Radaelli M; Immovilli P; Capobianco M; De Rossi N; Brichetto G; Cocco E; Scandellari C; Cavalla P; Pesci I; Zito A; Confalonieri P; Marfia GA; Perini P; Inglese M; Trojano M; Brescia Morra V; Tedeschi G; Comi G; Battaglia MA; Patti F; Salvetti M;
    Neurol Neuroimmunol Neuroinflamm; 2022 Jan; 9(1):. PubMed ID: 34753829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran.
    Safavi F; Nourbakhsh B; Azimi AR
    Mult Scler Relat Disord; 2020 Aug; 43():102195. PubMed ID: 32460086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COVID-19 infection and hospitalization rate in Iranian multiple sclerosis patients: What we know by May 2021.
    Naghavi S; Kavosh A; Adibi I; Shaygannejad V; Arabi S; Rahimi M; Mazaheri S; Ashtari F
    Mult Scler Relat Disord; 2022 Jan; 57():103335. PubMed ID: 35158427
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modifiable risk factors of COVID-19 in patients with multiple sclerosis: a single-centre case-control study.
    Montini F; Nozzolillo A; Rancoita PMV; Zanetta C; Moiola L; Cugnata F; Esposito F; Rocca MA; Martinelli V; Filippi M
    J Neurol; 2023 Apr; 270(4):1835-1842. PubMed ID: 36795147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. COVID-19 outcomes in patients with multiple sclerosis: Understanding changes from 2020 to 2022.
    Jeantin L; Januel E; Labauge P; Maillart E; de Seze J; Zéphir H; Pelletier J; Kerschen P; Biotti D; Heinzlef O; Guilloton L; Bensa C; Théaudin M; Vukusic S; Casez O; Maurousset A; Laplaud D; Berger E; Lebrun-Frenay C; Bourre B; Branger P; Stankoff B; Clavelou P; Thouvenot E; Manchon E; Moreau T; Sellal F; Zedet M; Papeix C; Louapre C
    Mult Scler; 2024 Mar; 30(3):381-395. PubMed ID: 38247113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.